Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease?

Nephrology Dialysis Transplantation

Volumn 18, Issue 11, 2003, Pages 2293-2299

  Boner, Geoffrey ^a,c,e,f   Cox, Alison J ^b   Kelly, Darren J ^b   Tobar, Ana ^c,e   Bernheim, Joëlle ^d,e   Langham, Robyn G ^b   Cooper, Mark E ^a   Gilbert, Richard E ^b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c RABIN MEDICAL CENTER   (Israel)

^d MEIR MEDICAL CENTER   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

^f NONE   (Israel)

Author keywords

In situ hybridization; Minimal change disease; VEGF

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; KIDNEY BIOPSY; KIDNEY PARENCHYMA; MALE; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; TISSUE REPAIR;

ADULT; AGED; CHILD; FEMALE; GLOMERULAR MESANGIUM; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; NEPHROSIS, LIPOID; NEPHROTIC SYNDROME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 0242383269     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg372     Document Type: Article

References (30)

1. Falk RJ, Jennette JC, Nachman PH. Primary glomerular diseases: minimal change disease. In: Brenner BM ed. The Kidney, 6th edn. WB Saunders Co., Philadelphia, PA: 1271-1277
2. Bailey E, Bottomley MJ, Westwell S et al. Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation. J Clin Pathol 1999; 52: 735-738
3. Brown LF, Berse B, Tognazzi K et al. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 1992; 42: 1457-1461
4. Shulman K, Rosen S, Tognazzi K, Manseau EJ, Brown LF. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol 1996; 7: 661-666
5. Webb NJ, Watson CJ, Roberts IS et al. Circulating vascular endothelial growth factor is not increased during relapses of steroid-sensitive nephrotic syndrome. Kidney Int 1999; 55: 1063-1071
6. Matsumoto K, Kanmatsuse K. Elevated vascular endothelial growth factor levels in the urine of patients with minimal-change nephrotic syndrome. Clin Nephrol 2001; 55: 269-274
7. Gilbert RE, Wu LL, Kelly DJ et al. Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis. Am J Pathol 1999; 155: 429-440
8. Gilbert RE, Vranes D, Berka JL et al. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest 1998; 78: 1017-1027
9. Mulder H, Ahrén B, Sundler F. Applications of in situ hybridization and immunocytochemistry for localization and quantification of gene expression - a lesson from islet amyloid peptide. In: Gu J, ed., Analytical Morphology - Theory, Applications and Protocols. Eaton Publishing, Natick, MA, 1996; 115-137
10. Baskin DG, Stahl WL. Fundamentals of quantitative autoradiography by computer densitometry for in situ hybridization, with emphasis on 33P. J Histochem Cytochem 1993; 41: 1767-1776
11. Ha IS, Um EY, Jung HR et al. Glucocorticoid diminishes vascular endothelial growth factor and exacerbates proteinuria in rats with mesangial proliferative glomerulonephritis. Am J Kidney Dis 2002; 39: 1001-1010
12. Horita Y, Miyazaki M, Koji T et al. Expression of vascular endothelial growth factor and its receptors in rats with protein-overload nephrosis. Nephrol Dial Transplant 1998; 13: 2519-2528
13. Ostendorf T, Kunter U, Eitner F et al. VEGF(165) mediates glomerular endothelial repair. J Clin Invest 1999; 104: 913-923
14. de Vriese AS, Tilton RG, Elger M et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993-1000
15. Fan L, Wakayama T, Yokoyama S, Amano O, Iseki S. Downregulation of vascular endothelial growth factor and its receptors in the kidney in rats with puromycin aminonucleoside nephrosis. Nephron 2002; 90: 95-102
16. Remuzzi G, Benigni A. Repairing renal lesions: will VEGF be the builder? Kidney Int 2000; 58: 2594-2595
17. Kanellis J, Fraser S, Katerelos M, Power DA. Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells. Am J Physiol Renal Physiol 2000; 278: F905-F915
18. Simon M, Rockl W, Hornig C et al. Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites. J Am Soc Nephrol 1998; 9: 1032-1044
19. Cooper ME, Vranes D, Youssef S et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 48: 2229-2239
20. Cheung PK, Klok PA, Bakker WW. Minimal change-like glomerular alterations induced by a human plasma factor. Nephron 1996; 74: 586-593
21. Cheung PK, Stulp B, Immenschuh S et al. Is 100KF an isoform of hemopexin? Immunochemical characterization of the vasoactive plasma factor 100KF. J Am Soc Nephrol 1999; 10: 1700-1708
22. Cheung PK, Klok PA, Baller JF, Bakker WW. Induction of experimental proteinuria in vivo following infusion of human plasma hemopexin. Kidney Int 2000; 57: 1512-1520
23. Matsumoto K, Ohi H, Kanmatsuse K. Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. Nephron 1997; 77: 212-218
24. Matsumoto K, Ohi H, Kanmatsuse K. Interleukin 12 upregulates the release of vascular permeability factor by peripheral blood mononuclear cells from patients with lipoid nephrosis. Nephron 1998; 78: 403-409
25. Matsumoto K, Ohi H, Kanmatsuse K. Effects of interleukin-15 on vascular permeability factor release by peripheral blood mononuclear cells in normal subjects and in patients with minimal-change nephrotic syndrome. Nephron 1999; 82: 32-38
26. Wiesener MS, Munchenhagen PM, Berger I et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res, 2001; 61: 5215-5222
27. Tomisawa M, Tokunaga T, Oshika Y et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer, 1999; 35: 133-137
28. Nicol D, Hii SI, Walsh M et al. Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol 1997; 157: 1482-1486
29. Kang DH, Johnson RJ. Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis. Curr Opin Nephrol Hypertens 2003; 12: 43-49
30. Iruela-Arispe L, Gordon K, Hugo C et al. Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol 1995; 147: 1715-1727